IOVA
IOVANCE BIOTHERAPEUTICS, INC.
$4.00
-5.44%
$1.7B
No data for this timeframe.
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (81%)
Inst. Holders8 funds
Inst. Value$165.2M
Inst. Activity5 buys / 1 sells
Reddit Sentiment70° Bullish
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001425205·Prev Close $4.23
Recent Activity
Jun 5, 2026
Insider
Vogt Frederick G sold 15,625 shares
Interim CEO & General Counsel @ $0.00 ($0.00)
Jun 5, 2026
Insider
GRAF FINCKENSTEIN FRIEDRICH sold 7,813 shares
Chief Medical Officer @ $0.00 ($0.00)
Jun 5, 2026
Insider
GRAF FINCKENSTEIN FRIEDRICH sold 3,976 shares
Chief Medical Officer @ $4.23 ($16.8K)
Jun 3, 2026
other
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
<p align="center"><em>First T cell therapy for a solid tumor cancer and first treatment option appro
May 22, 2026
Press
Iovance Biotherapeutics granted inducement stock options covering 93,340 shares to 13 new non-executive employees under
Impact 2/10
Apr 28, 2026
SEC
Iovance Biotherapeutics filed additional definitive proxy materials for its 2026 Annual Meeting, with proposals includin
DEFA14A — Impact 3/10
Apr 27, 2026
SEC
Iovance Biotherapeutics issued a press release announcing an upcoming earnings call for Q1 2026 financial results, but d
PRESS-RELEASE — Impact 3/10
Inst.
BANK OF AMERICA CORP — DOUBLED
14,277,813 shares ($39.0M)
Price Targets
$8.80
+126.8% upside
Strong Buy
Current $3.88
Low $4.00
Median $9.50
High $14.00
10 analysts
$4.00
$14.00
Analyst Ratings
3Strong Buy
10Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 8, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Apr 10, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 5, 2026 | UBS | MAINTAIN | Neutral → Neutral |
| Mar 3, 2026 | Citizens | UPGRADE | Market Perform → Market Outperform |
| Feb 25, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.13 ▲ +4.4% | $-0.16 — $-0.11 | 59% YoY | 8 |
| Next Q | $-0.12 ▲ +1.1% | $-0.17 — $-0.09 | 50% YoY | 8 |
| Current FY | $-0.56 ▼ -4.3% | $-0.72 — $-0.46 | 48% YoY | 8 |
| Next FY | $-0.32 ▼ -14.7% | $-0.46 — $-0.23 | 43% YoY | 7 |
Latest Reports
NEUTRAL
Press
2/10
Iovance Biotherapeutics granted inducement stock options covering 93,340 shares to 13 new non-executive employees under
May 22, 2026
NEUTRAL
DEFA14A
3/10
Iovance Biotherapeutics filed additional definitive proxy materials for its 2026 Annual Meeting, with proposals includin
Apr 28, 2026
NEUTRAL
PRESS-RELEASE
3/10
Iovance Biotherapeutics issued a press release announcing an upcoming earnings call for Q1 2026 financial results, but d
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $74.3M | — |
| BANK OF AMERICA CORP | $39.0M | DOUBLED |
| MORGAN STANLEY | $25.1M | ADD |
| TWO SIGMA INVESTMENTS, LP | $12.0M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $7.5M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Vogt Frederick | M | $0.00 |
| Jun 5, 2026 | GRAF FINCKENSTEIN | M | $0.00 |
| Jun 5, 2026 | GRAF FINCKENSTEIN | F | $16.8K |
| Jun 5, 2026 | GRAF FINCKENSTEIN | M | $0.00 |
| Jun 5, 2026 | Puri Raj | F | $16.3K |
Reddit Sentiment
70°▼
Bullish
Bearish
Neutral
Bullish
8 institutional holders with $165.2M total value (60,503,474 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, MORGAN. Net buying activity: 5 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 27,207,079 | $74.3M | 45.0% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 14,277,813 | $39.0M | 23.6% | DOUBLED +127.4% |
| 3 | MORGAN STANLEY | 9,191,840 | $25.1M | 15.2% | ADD +64.7% |
| 4 | TWO SIGMA INVESTMENTS, LP | 4,397,989 | $12.0M | 7.3% | ADD +60.5% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,753,343 | $7.5M | 4.6% | ADD +30.7% |
| 6 | WELLS FARGO & COMPANY/MN | 1,993,337 | $5.4M | 3.3% | ADD +31.4% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 651,000 | $1.8M | 1.1% | NEW |
| 8 | FMR LLC | 31,073 | $84.8K | 0.1% | TRIM -28.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 6,279,230 | 14,277,813 | +127.4% | $39.0M | 2025-Q4 |
| MORGAN STANLEY | ADD | 5,581,563 | 9,191,840 | +64.7% | $25.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 2,740,854 | 4,397,989 | +60.5% | $12.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 1,517,364 | 1,993,337 | +31.4% | $5.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 651,000 | — | $1.8M | 2025-Q4 |
| FMR LLC | TRIM | 43,581 | 31,073 | -28.7% | $84.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 4,029,568 | 6,279,230 | +55.8% | $13.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 4,633,451 | 2,740,854 | -40.8% | $5.9M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,916,486 | 2,504,542 | +30.7% | $5.4M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 1,074,250 | 1,517,364 | +41.2% | $3.3M | 2025-Q3 |
| UBS Group AG | TRIM | 1,779,412 | 936,504 | -47.4% | $2.0M | 2025-Q3 |
| FMR LLC | ADD | 33,779 | 43,581 | +29.0% | $94.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 4,887,200 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 4,018,374 | 6,450,933 | +60.5% | $11.1M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 3,511,400 | 4,887,200 | +39.2% | $8.4M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 396,994 | 4,633,451 | +1067.1% | $8.0M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 3,017,185 | 4,029,568 | +33.6% | $6.9M | 2025-Q2 |
| UBS Group AG | TRIM | 2,496,749 | 1,779,412 | -28.7% | $3.1M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 858,570 | 1,074,250 | +25.1% | $1.8M | 2025-Q2 |
| FMR LLC | TRIM | 82,826 | 33,779 | -59.2% | $58.1K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 3,511,400 | — | $11.7M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 580,245 | 858,570 | +48.0% | $2.9M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 396,994 | — | $1.3M | 2025-Q1 |
| FMR LLC | TRIM | 117,439 | 82,826 | -29.5% | $275.8K | 2025-Q1 |
| NORGES BANK | EXIT | 416,237 | 0 | -100.0% | $0.00 | 2025-Q1 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M | 15,625 | $0.00 | $0.00 |
| Jun 5, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | M | 7,813 | $0.00 | $0.00 |
| Jun 5, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | F | 3,976 | $4.23 | $16.8K |
| Jun 5, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | M | 7,813 | $0.00 | $0.00 |
| Jun 5, 2026 | Puri Raj K. | Chief Regulatory Officer | F | 3,843 | $4.23 | $16.3K |
| Jun 5, 2026 | Puri Raj K. | Chief Regulatory Officer | M | 9,766 | $0.00 | $0.00 |
| Jun 5, 2026 | Vogt Frederick G | Interim CEO & General Counsel | F | 6,638 | $4.23 | $28.1K |
| Jun 5, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M | 15,625 | $0.00 | $0.00 |
| Jun 5, 2026 | BILINSKY IGOR | Chief Operating Officer | M | 7,813 | $0.00 | $0.00 |
| Jun 5, 2026 | BILINSKY IGOR | Chief Operating Officer | F | 3,976 | $4.23 | $16.8K |
| Jun 5, 2026 | BILINSKY IGOR | Chief Operating Officer | M | 7,813 | $0.00 | $0.00 |
| Jun 5, 2026 | Puri Raj K. | Chief Regulatory Officer | M | 9,766 | $0.00 | $0.00 |
| Jun 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | F | 17,701 | $3.96 | $70.1K |
| Jun 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M | 41,668 | $0.00 | $0.00 |
| Jun 1, 2026 | Puri Raj K. | Chief Regulatory Officer | M | 5,469 | $0.00 | $0.00 |
| Jun 1, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | M | 8,790 | $0.00 | $0.00 |
| Jun 1, 2026 | Puri Raj K. | Chief Regulatory Officer | F | 2,508 | $3.96 | $9.9K |
| Jun 1, 2026 | Puri Raj K. | Chief Regulatory Officer | M | 5,469 | $0.00 | $0.00 |
| Jun 1, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | M | 8,790 | $0.00 | $0.00 |
| Jun 1, 2026 | BILINSKY IGOR | Chief Operating Officer | M | 8,790 | $0.00 | $0.00 |
| Jun 1, 2026 | BILINSKY IGOR | Chief Operating Officer | F | 4,473 | $3.96 | $17.7K |
| Jun 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M | 41,668 | $0.00 | $0.00 |
| Jun 1, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | F | 4,473 | $3.96 | $17.7K |
| Jun 1, 2026 | BILINSKY IGOR | Chief Operating Officer | M | 8,790 | $0.00 | $0.00 |
| May 11, 2026 | Kirby Daniel Gordon | Chief Commercial Officer | M | 10,000 | $0.00 | $0.00 |
| May 11, 2026 | Kirby Daniel Gordon | Chief Commercial Officer | F | 2,435 | $3.70 | $9.0K |
| May 11, 2026 | Kirby Daniel Gordon | Chief Commercial Officer | M | 10,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Kirby Daniel Gordon | Chief Commercial Officer | A | 132,200 | $0.00 | $0.00 |
| Mar 9, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | A | 58,750 | $0.00 | $0.00 |
| Mar 9, 2026 | Puri Raj K. | Chief Regulatory Officer | A | 117,500 | $0.00 | $0.00 |
| Mar 9, 2026 | Vogt Frederick G | Interim CEO & General Counsel | A | 235,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Roche Corleen M. | Chief Financial Officer | A | 132,200 | $0.00 | $0.00 |
| Mar 9, 2026 | BILINSKY IGOR | Chief Operating Officer | A | 117,500 | $0.00 | $0.00 |
| Mar 5, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M | 62,493 | $0.00 | $0.00 |
| Mar 5, 2026 | Puri Raj K. | Chief Regulatory Officer | M | 39,059 | $0.00 | $0.00 |
| Mar 5, 2026 | BILINSKY IGOR | Chief Operating Officer | M | 31,246 | $0.00 | $0.00 |
| Mar 5, 2026 | BILINSKY IGOR | Chief Operating Officer | M | 31,246 | $0.00 | $0.00 |
| Mar 5, 2026 | Puri Raj K. | Chief Regulatory Officer | M | 39,059 | $0.00 | $0.00 |
| Mar 5, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M | 62,493 | $0.00 | $0.00 |
| Mar 5, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | M | 31,246 | $0.00 | $0.00 |
| Mar 5, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | M | 31,246 | $0.00 | $0.00 |
| Mar 2, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M | 41,669 | $0.00 | $0.00 |
| Mar 2, 2026 | BILINSKY IGOR | Chief Operating Officer | M | 8,790 | $0.00 | $0.00 |
| Mar 2, 2026 | Puri Raj K. | Chief Regulatory Officer | M | 5,470 | $0.00 | $0.00 |
| Mar 2, 2026 | Puri Raj K. | Chief Regulatory Officer | M | 5,470 | $0.00 | $0.00 |
| Mar 2, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | M | 8,790 | $0.00 | $0.00 |
| Mar 2, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M | 52,087 | $0.00 | $0.00 |
| Mar 2, 2026 | BILINSKY IGOR | Chief Operating Officer | M | 12,307 | $0.00 | $0.00 |
| Mar 2, 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | M | 12,697 | $0.00 | $0.00 |
| Feb 24, 2026 | Kirby Daniel Gordon | Chief Commercial Officer | M | 150,000 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.0/10.
Current analyst consensus: Strong Buy (81% buy). Based on 16 analysts: 3 strong buy, 10 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.80 mean target
+126.8% upside
Strong Buy (1.60)
$4.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $3.88 |
| Target Low | $4.00 |
| Target Mean | $8.80 |
| Target Median | $9.50 |
| Target High | $14.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.13 | $-0.16 | $-0.11 | 59.2% | +4.4% | 1↑ 2↓ | $0.1B | 46.4% | 8 |
| Next Q 2026-09-30 |
$-0.12 | $-0.17 | $-0.09 | 50.1% | +1.1% | 1↑ 2↓ | $0.1B | 41.6% | 8 |
| Current FY 2026-12-31 |
$-0.56 | $-0.72 | $-0.46 | 48.2% | -4.3% | 2↑ 4↓ | $0.4B | 37.1% | 8 |
| Next FY 2027-12-31 |
$-0.32 | $-0.46 | $-0.23 | 43.5% | -14.7% | 2↑ 4↓ | $0.5B | 44.7% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.135 | |
| 7d ago | $-0.135 | |
| 30d ago | $-0.141 | +0.006 |
| 60d ago | $-0.130 | -0.005 |
| 90d ago | $-0.130 | -0.005 |
4 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 8, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Mar 3, 2026 | Citizens | UPGRADE | Market Perform | Market Outperform |
| Feb 25, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | Citizens | UPGRADE | Market Perform | Market Outperform |
| Dec 17, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 10 | 3 | 0 | 0 | 81% | |
| May 1, 2026 | 3 | 10 | 4 | 0 | 0 | 76% | |
| Apr 1, 2026 | 3 | 10 | 4 | 0 | 0 | 76% | |
| Mar 1, 2026 | 3 | 10 | 4 | 0 | 0 | 76% | |
| Feb 1, 2026 | 3 | 9 | 5 | 1 | 0 | 67% | |
| Jan 1, 2026 | 3 | 9 | 5 | 1 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
70°
Bullish
Bearish
Neutral
Bullish
18 mentions
11 bullish
2 bearish
16 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 25, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 24, 2026 | 3 | 64° Warm | 2 | 0 | 3 |
| Feb 23, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
IOVA boom or bust?
▲ 1
💬 0
⚡ 0.5
$IOVA
▲ 1
💬 1
⚡ 0.5
IOVA stock
▲ 1
💬 0
⚡ 0.5
Never thought I'd make post like this. $IOVA
▲ 1
💬 0
⚡ 0.5
Biotech companies $IOVA and $NMRA DD
▲ 1
💬 1
⚡ 0.0
IOVA heavy SI interest 🚀🚀
▲ 1
💬 4
⚡ 0.0
IOVA short squeezing right now 🚀🚀🚀
▲ 1
💬 1
⚡ 0.0
Thank you IOVA
▲ 39
💬 22
⚡ 1.7
IOVA Strong 25Q4 Earnings Call
▲ 72
💬 40
⚡ 3.4
IOVA DD
▲ 1
💬 1
⚡ 0.0
IOVA GAINZ 🚀🚀🚀
▲ 1
💬 1
⚡ 0.0
Premium Higher than Share Price
▲ 16
💬 13
⚡ 0.4
Jun 3, 2026
other
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
<p align="center"><em>First T cell therapy for a solid tumor cancer and first treatment option approved </em><em>in Australia for advanced melanoma af
Jun 1, 2026
other
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
<p align="center"><em>Next-Generation Platform Expands into Solid Tumors </em><br><em>Representing 100,000+ U.S. Deaths Annually</em></p>
May 22, 2026
announcement
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
<p>SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology c
May 21, 2026
other
Iovance Biotherapeutics to Present at Upcoming Conference
<p>SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating,
May 16, 2026
Clinical Trial
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Phase Phase 2 — TERMINATED
May 8, 2026
short_interest
FTD: IOVA — 224,151 shares ($0.8M) failed to deliver
Settlement: 20260508, Price: $3.55, FTD Value: $795,736.05, IOVANCE BIOTHERAPEUTICS INC CO
May 7, 2026
earnings
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
<p align="center"><em>1Q26 Total Revenue of ~$71M Delivers ~</em><em>45% Year-over-Year Growth</em></p>
May 7, 2026
earnings_calendar
IOVA Q1 2026 Earnings Scheduled — 2026-05-07
May 1, 2026
short_volume
Short Volume: IOVA — 58.8% short (3.6M / 6.2M)
Short: 3,629,164 | Exempt: 1,337 | TRF Vol: 6,168,784 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
Clinical Trial
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
Phase Phase 2 — COMPLETED
Apr 28, 2026
short_volume
Short Volume: IOVA — 61.7% short (4.6M / 7.5M)
Short: 4,635,122 | Exempt: 11,174 | TRF Vol: 7,514,831 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
earnings
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
<p>SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovatin
Apr 22, 2026
short_volume
Short Volume: IOVA — 63.0% short (8.1M / 12.9M)
Short: 8,149,181 | Exempt: 47,547 | TRF Vol: 12,934,809 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
activist
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
<p>SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology
Apr 13, 2026
short_volume
Short Volume: IOVA — 56.8% short (5.7M / 10.1M)
Short: 5,722,400 | Exempt: 58,069 | TRF Vol: 10,071,621 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: IOVA — 58.7% short (12.8M / 21.8M)
Short: 12,808,902 | Exempt: 52,252 | TRF Vol: 21,824,777 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: IOVA — 60.3% short (4.8M / 7.9M)
Short: 4,785,699 | Exempt: 11,950 | TRF Vol: 7,941,137 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
Phase Phase 2 — COMPLETED